CoChat

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

Open access
Pollyea, Daniel A., Pratz, Keith, Letai, Anthony, Jonas, Brian A., Wei, Andrew H., Pullarkat, Vinod, Konopleva, Marina, Thirman, Michael J., Arellano, Martha, Becker, Pamela S., Chyla, Brenda, Hong, Wan‐Jen, Jiang, Qi, Potluri, Jalaja, DiNardo, Courtney D. · 2021 · American Journal of Hematology
Cited by 166

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia (AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in an open‐label, non‐randomized, multicenter phase 1b trial of venetoclax with azacitidine (AZA; 75 mg/m 2; days 1‐7) or decitabine (DEC; 20 mg/m 2; days 1‐5). Endpoints included safety, response rates (complete remission [CR], CR with incomplete blood count recovery [CRi]), response duration and overall survival (OS). The median follow‐up time was 29 and 40 months for patients treated with venetoclax plus AZA and DEC combinations, respectively. Key Grade ≥ 3 AEs (AZA and DEC) were febrile neutropenia (39% and 65%), anemia (30% and 26%), thrombocytopenia (25% and 23%), and neutropenia (20% and 10%). The CR/CRi rate was 71% for venetoclax plus AZA and 74% for venetoclax plus DEC. The median duration of CR/CRi was 21.9 months and 15.0 months, and the median OS was 16.4 months and 16.2 months, for venetoclax plus AZA and DEC, respectively. These results support venetoclax plus hypomethylating agents as highly effective frontline AML therapies for patients unfit for intensive chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ajh.26039

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Metadata

Authors
Pollyea, D. A., Pratz, K., Letai, A., Jonas, B. A., Wei, A. H., Pullarkat, V., Konopleva, M., Thirman, M. J., Arellano, M., Becker, P. S., Chyla, B., Hong, W., Jiang, Q., Potluri, J., & DiNardo, C. D.
Venue
American Journal of Hematology
Publisher
Wiley
Published
2020-11-10
Volume
96
Issue
2
Pages
208-217
ISSN
  • 0361-8609 (ISSN-L)
  • 1096-8652
OpenAlex
W3095201154
Cited by
166
References
10
FWCI
13.64
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study. https://app.cochat.ai/papers/10.1002/ajh.26039
The paper
Pollyea, D. A., Pratz, K., Letai, A., Jonas, B. A., Wei, A. H., Pullarkat, V., Konopleva, M., Thirman, M. J., Arellano, M., Becker, P. S., Chyla, B., Hong, W., Jiang, Q., Potluri, J., & DiNardo, C. D. (2021). Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study. American Journal of Hematology. https://doi.org/10.1002/ajh.26039

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.